Search Results - jeffrey+loeb

3 Results

Sort By:

Long non-protein-coding RNA molecules as therapeutics for epilepsy.

Long Non-Coding RNA Molecules as Therapeutics for Epilepsy WSU Tech#: 12-1089 Technology Summary: Long Non-coding RNA (lncRNA) were first described in 2002 from mouse, making this a relatively new technology. lncRNA transcripts far exceed the number of protein coding mRNAs in the mammalian transcriptome, but in lower copy numbers. Inventors...

Published: 10/5/2023 | Inventor(s): Jeffrey Loeb, Leonard Lipovich

Keywords(s):

Category(s): Medical, Bioinformatics, Biomedical, Biotechnology, Diagnostic, Diagnostics, Drug Discovery, Pharmaceuticals, Therapeutics

GlyB4 Fusion with Neuregulin Heparin-Targeting Domain to Block Neuregulin Signaling

We have harnessed this natural targeting ability of NRG by fusing the HBD of NRG to soluble HER4. This fusion protein retains high affinity heparin binding to heparin and to cells that express heparan sulfates resulting in a more potent NRG antagonist. In vivo, it is targeted to peripheral nerve segments where it blocks the activity of NRG as a Schwann...

Published: 12/6/2022 | Inventor(s): Jeffrey Loeb, Qunfang Lee

Keywords(s): Anti-cancer, Biotechnology, Cancer risk, Cancer Therapies, Drug Delivery, Drug Target, Epilepsy

Category(s): Life Science, Drug Delivery, Other

Functional Improvements in Fahr Disease

Detailed Description Idiopathic cerebral calcification (a.k.a. Brain Stones) can be associated with a progressive neurological disorder for which there is no known treatment. This invention is a repurposing of an existing FDA approved compound for a new use. It relates to the treatment of Fahr?s Disease by the administration of a class of drugs...

Published: 11/17/2014 | Inventor(s): Jeffrey Loeb

Keywords(s):

Category(s): Pharmaceuticals